Sarzi-Puttini Piercarlo, Perrot Serge, Perez-Cajaraville Juan, Fornasari Diego Maria Michele, Radaelli Franco, Varrassi Giustino
Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy.
IRCCS Ospedale Galeazzi Sant'Ambrogio, Milan, Italy.
Pain Ther. 2025 Jun;14(3):891-912. doi: 10.1007/s40122-025-00735-5. Epub 2025 Apr 23.
Ibuprofen arginine (IBA) combines well-established analgesic and anti-inflammatory properties with enhanced pharmacokinetics. The addition of arginine significantly improves solubility and absorption, leading to a faster onset of action compared to conventional ibuprofen. Clinical studies consistently demonstrate that IBA achieves meaningful pain relief within a shorter timeframe while maintaining a favorable safety profile. IBA's rapid action is particularly valuable in managing acute exacerbations of chronic pain and preventing central sensitization, thus improving patient comfort, adherence, and overall quality of life. By addressing both the inflammatory and nociceptive components of pain, IBA offers an effective and well-tolerated alternative in multimodal pain management strategies. This review explores the clinical benefits of IBA in pain management among various clinical settings.
精氨酸布洛芬（IBA）结合了公认的镇痛和抗炎特性以及改善的药代动力学。精氨酸的添加显著提高了溶解度和吸收率，与传统布洛芬相比，起效更快。临床研究一致表明，IBA在更短的时间内实现了有意义的疼痛缓解，同时保持了良好的安全性。IBA的快速起效在处理慢性疼痛的急性加重和预防中枢敏化方面特别有价值，从而提高了患者的舒适度、依从性和整体生活质量。通过解决疼痛的炎症和伤害感受成分，IBA在多模式疼痛管理策略中提供了一种有效且耐受性良好的替代方案。本综述探讨了IBA在各种临床环境中疼痛管理的临床益处。
